ScholarLens Back to search
2020•InfectionOpen access

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

Alix T. Coste, Antonios Kritikos, Jizhou Li, Nina Khanna, Daniel Goldenberger, Christian Garzoni, C. Zehnder, Katia Boggian, Dionysios Neofytos, Arnaud Riat, Daniel Bachmann, Dominique Sanglard, Frédéric Lamoth, The Fungal Infection Network of Switzerland (FUNGINOS), Frédéric Lamoth, Nina Khanna, Katia Boggian, Dominique Sanglard

Open full text 75 citations

Abstract

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

Open-access reader

About this research paper

What this paper is about

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

Why it matters

OpenAlex reports 75 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

Key concepts: Echinocandin, Echinocandins, Candida glabrata, Candida albicans, Medicine, Microbiology, Candida auris, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland — Research Paper | ScholarLens